1. Home
  2. FSHP vs HLVX Comparison

FSHP vs HLVX Comparison

Compare FSHP & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSHP
  • HLVX
  • Stock Information
  • Founded
  • FSHP 2018
  • HLVX 2020
  • Country
  • FSHP United States
  • HLVX United States
  • Employees
  • FSHP N/A
  • HLVX N/A
  • Industry
  • FSHP
  • HLVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FSHP
  • HLVX Health Care
  • Exchange
  • FSHP NYSE
  • HLVX Nasdaq
  • Market Cap
  • FSHP 92.2M
  • HLVX 83.7M
  • IPO Year
  • FSHP 2024
  • HLVX 2022
  • Fundamental
  • Price
  • FSHP $10.42
  • HLVX $1.92
  • Analyst Decision
  • FSHP
  • HLVX Hold
  • Analyst Count
  • FSHP 0
  • HLVX 5
  • Target Price
  • FSHP N/A
  • HLVX $2.33
  • AVG Volume (30 Days)
  • FSHP 173.0
  • HLVX 199.3K
  • Earning Date
  • FSHP 01-01-0001
  • HLVX 08-07-2025
  • Dividend Yield
  • FSHP N/A
  • HLVX N/A
  • EPS Growth
  • FSHP N/A
  • HLVX N/A
  • EPS
  • FSHP 0.21
  • HLVX N/A
  • Revenue
  • FSHP N/A
  • HLVX N/A
  • Revenue This Year
  • FSHP N/A
  • HLVX N/A
  • Revenue Next Year
  • FSHP N/A
  • HLVX N/A
  • P/E Ratio
  • FSHP $48.99
  • HLVX N/A
  • Revenue Growth
  • FSHP N/A
  • HLVX N/A
  • 52 Week Low
  • FSHP $9.99
  • HLVX $1.34
  • 52 Week High
  • FSHP $10.54
  • HLVX $15.60
  • Technical
  • Relative Strength Index (RSI)
  • FSHP N/A
  • HLVX 50.88
  • Support Level
  • FSHP N/A
  • HLVX $1.93
  • Resistance Level
  • FSHP N/A
  • HLVX $2.07
  • Average True Range (ATR)
  • FSHP 0.00
  • HLVX 0.07
  • MACD
  • FSHP 0.00
  • HLVX -0.00
  • Stochastic Oscillator
  • FSHP 0.00
  • HLVX 40.00

About FSHP FLAG SHIP ACQUISITION CORPORATION

Flag Ship Acquisition Corp is a blank check company formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.

About HLVX HilleVax Inc.

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Share on Social Networks: